Antiproliferative Effect of Methyl-β-Cyclodextrin in Cancer Treatment
Author Information
Author(s): PY Grosse, F Bressolle, F Pinguet
Primary Institution: Val d'Aurelle Anticancer Center, Montpellier, France
Hypothesis
Can methyl-β-cyclodextrin (MEBCD) effectively reduce tumor growth in human cancer models compared to doxorubicin?
Conclusion
Methyl-β-cyclodextrin significantly reduced tumor volume in both MCF7 and A2780 cancer models without notable toxicity.
Supporting Evidence
- MEBCD reduced tumor volume by at least twofold compared to control groups.
- MEBCD was more effective than doxorubicin in the MCF7 model.
- No significant toxicity was observed in mice treated with MEBCD.
Takeaway
Methyl-β-cyclodextrin can help shrink tumors in mice without making them sick, which is good news for cancer treatment.
Methodology
In vitro and in vivo studies were conducted using MCF7 and A2780 cancer cell lines and xenografted mice, with MEBCD administered at varying doses.
Limitations
The study was limited to specific cancer cell lines and animal models, which may not fully represent human responses.
Participant Demographics
Female Swiss nude mice aged 5 weeks and weighing 20-22 g were used for the in vivo studies.
Statistical Information
P-Value
<0.01
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website